Watch live: House grills FDA commissioner, Abbott executive on baby formula shortage

Watch live: House grills FDA commissioner, Abbott executive on baby formula shortage


[The stream is slated to start at 11 a.m. ET. Please refresh the page if you do not see a player above at that time.]

The head of the Food and Drug Administration and executives from the infant formula industry are set to answer questions from House lawmakers Wednesday about the nationwide shortage that has left parents struggling to find food for their infants.

The House Oversight and Investigations subcommittee hearing will begin at 11 a.m. Lawmakers will question FDA Commissioner Robert Califf, FDA food policy chief Frank Yiannis, and the director of the FDA’s food safety center Susan Mayne during the first portion of the hearing.

The FDA has come under scrutiny from lawmakers for not acting quickly enough to inspect Abbott Nutrition’s infant formula plant in Sturgis, Mich., after a whistleblower warned the agency in October about food safety violations at the plant. The FDA didn’t initiate inspections of the plant until late January, ultimately finding five different strains of Cronobacter – a bacteria that can cause a dangerous blood infection – at the facility.

Four infants who consumed powdered formula from the Abbott plant fell ill and were hospitalized with Cronobacter infections, two of whom died. The FDA, in testimony released ahead of the hearing, said it does not have definitive evidence proving proving the bacteria found at the plant caused the infant illnesses. None of the Cronobacter strains at the Sturgis plant matched two clinical samples from the ill infants, according to the FDA. However, the agency said Cronobacter found at manufacturing plants is considered one of the most likely sources of contaminated infant formula.

Abbott shut down the plant and initiated a voluntary of recall of several products in February, contributing to an infant formula shortage that has left store shelves empty in many parts of the country. Four manufacturers – Abbott, Mead Johnson Nutrition, Nestle USA and Perrigo – control 90% of the domestic infant formula market in the U.S.

House lawmakers will also question Abbott executive Christopher Calamari, Gerber Vice President Scott Fritz, and Reckitt Senior Vice President Robert Cleveland. Nestle owns Gerber and Mead Johnson merged with Reckitt in 2017.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push
Business

Sen. Warren blasts CFPB director for undermining Trump’s credit card affordability push

U.S. Senator Elizabeth Warren (D-MA) and Director of the United States Office of Management and Budget, Russell Vought. Kevin Mohatt | Kevin Lamarque | | Reuters Sen. Elizabeth Warren on Friday accused the acting head of the Consumer Financial Protection Bureau of undermining President Donald Trump’s stated push to make credit cards more affordable, according […]

Read More
Why a niche category of CRE lending is suddenly seeing record deals
Business

Why a niche category of CRE lending is suddenly seeing record deals

Wepro | Moment | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large public companies. Sign up to receive future editions, straight […]

Read More
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Business

What obesity drugmakers see next in the market: More pills, easier access and drug combinations

A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | Bloomberg | Getty Images The future of the booming obesity drug market won’t hinge on drugs that deliver greater weight loss alone.  Top executives from drugmakers big and small told CNBC that the next phase […]

Read More